IceCure Medical Ltd. (NASDAQ:ICCM - Get Free Report)'s stock price shot up 0.8% on Wednesday . The stock traded as high as $0.98 and last traded at $0.95. 125,625 shares traded hands during trading, a decline of 73% from the average session volume of 469,709 shares. The stock had previously closed at $0.94.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "buy" rating and issued a $2.50 price objective on shares of IceCure Medical in a research report on Thursday, May 29th.
View Our Latest Research Report on ICCM
IceCure Medical Stock Performance
The company has a debt-to-equity ratio of 0.02, a current ratio of 1.89 and a quick ratio of 1.48. The firm has a fifty day moving average price of $1.06 and a two-hundred day moving average price of $1.17. The stock has a market capitalization of $52.79 million, a PE ratio of -3.40 and a beta of 0.33.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last released its earnings results on Wednesday, May 28th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. The business had revenue of $0.73 million for the quarter, compared to analyst estimates of $0.75 million. IceCure Medical had a negative return on equity of 182.26% and a negative net margin of 467.37%. During the same quarter last year, the firm posted ($0.08) earnings per share. Research analysts expect that IceCure Medical Ltd. will post -0.28 EPS for the current year.
Hedge Funds Weigh In On IceCure Medical
A hedge fund recently raised its stake in IceCure Medical stock. Geode Capital Management LLC lifted its stake in shares of IceCure Medical Ltd. (NASDAQ:ICCM - Free Report) by 58.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 40,453 shares of the company's stock after acquiring an additional 14,893 shares during the quarter. Geode Capital Management LLC owned approximately 0.07% of IceCure Medical worth $44,000 at the end of the most recent reporting period. 0.62% of the stock is currently owned by hedge funds and other institutional investors.
About IceCure Medical
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Read More
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
